- Home
- BAFN vs BOLD Comparison
BAFN vs BOLD Comparison
Compare BAFN & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAFN
- BOLD
- Stock Information
- Founded
- BAFN 1999
- BOLD 2018
- Country
- BAFN United States
- BOLD United States
- Employees
- BAFN N/A
- BOLD N/A
- Industry
- BAFN Savings Institutions
- BOLD
- Sector
- BAFN Finance
- BOLD
- Exchange
- BAFN Nasdaq
- BOLD Nasdaq
- Market Cap
- BAFN 40.6M
- BOLD 33.4M
- IPO Year
- BAFN N/A
- BOLD 2024
- Fundamental
- Price
- BAFN $8.34
- BOLD $1.25
- Analyst Decision
- BAFN
- BOLD Buy
- Analyst Count
- BAFN 0
- BOLD 4
- Target Price
- BAFN N/A
- BOLD $4.00
- AVG Volume (30 Days)
- BAFN 8.2K
- BOLD 128.3K
- Earning Date
- BAFN 10-30-2025
- BOLD 11-05-2025
- Dividend Yield
- BAFN 2.91%
- BOLD N/A
- EPS Growth
- BAFN N/A
- BOLD N/A
- EPS
- BAFN N/A
- BOLD N/A
- Revenue
- BAFN $58,931,000.00
- BOLD N/A
- Revenue This Year
- BAFN N/A
- BOLD N/A
- Revenue Next Year
- BAFN N/A
- BOLD N/A
- P/E Ratio
- BAFN N/A
- BOLD N/A
- Revenue Growth
- BAFN N/A
- BOLD N/A
- 52 Week Low
- BAFN $6.40
- BOLD $1.00
- 52 Week High
- BAFN $19.75
- BOLD $3.75
- Technical
- Relative Strength Index (RSI)
- BAFN 35.33
- BOLD 44.00
- Support Level
- BAFN $8.05
- BOLD $1.15
- Resistance Level
- BAFN $8.65
- BOLD $1.28
- Average True Range (ATR)
- BAFN 0.32
- BOLD 0.06
- MACD
- BAFN -0.11
- BOLD -0.03
- Stochastic Oscillator
- BAFN 18.85
- BOLD 29.11
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.